Skip to main content
Premium Trial:

Request an Annual Quote

Capital Genomix and Blanchette Rockefeller Neurosciences Institute to Build Microarray Facility

NEW YORK, May 30 -- Capital Genomix and the Blanchette Rockefeller Neurosciences Institute plan to establish a microarray core facility, Capital said yesterday.

 

The facility, to be housed at JohnsHopkinsUniversity's Shady Grove campus in Gaithersburg, Md., will be headed by microarray researcher Pachiappan Manickam.

 

Capital, based in Chantilly, Va., holds a microarray service license from Affymetrix. The company expects the collaboration with BRNI will expand to include its own gene expression and antibody technologies, called GeneSystem320 and ImmunoMouse, respectively.

 

BRNI is a non-profit institute focusing on translational research in the area of Alzheimer's disease.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.